

**Amendments to the Specification**

Please replace the paragraph on page 2, beginning with "The experimental results", with the following amended paragraph:

The experimental results demonstrate that the intravenous composition of the present invention exert a strong abruptive effect on the membranes on cancer cells, such as leukemic cells. ~~The intravenous composition of the present invention may also incorporate a pH-buffering agent in order to control the pH for effective and safe administration of the composition to patients. The pH-buffering agent is selected from the group consisting of hydrochloric acid (HCL), alkali hydroxide, such a sodium hydroxide, or carbonate solutions, as taught by Merck Index, 10<sup>th</sup> Ed. 1983, p. 117 (compound 824—arsenic trioxide).~~ It inhibits DNA/RNA synthesis and reduces the proliferation of the leukemic cells. The experiments, both *in vivo* and *in vitro* have demonstrated that the intravenous composition of the present invention is effective in destroying leukemic cells while inducing increased cells differentiation to produce normal cells. Additionally, the recovery of hematopoietic function is accelerated. It has also been found that the composition of the present invention can pass through the blood-brain barrier.